Sionna Therapeutics (NASDAQ:SION) Sets New 1-Year High – Here’s What Happened

Sionna Therapeutics, Inc. (NASDAQ:SION) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $45.00 and last traded at $44.23, with a volume of 303 shares trading hands. The stock had previously closed at $43.30.

Analyst Upgrades and Downgrades

SION has been the topic of several research reports. Citigroup initiated coverage on shares of Sionna Therapeutics in a research report on Tuesday, February 24th. They issued an “outperform” rating on the stock. Guggenheim upped their target price on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. BTIG Research reaffirmed a “buy” rating and set a $58.00 target price on shares of Sionna Therapeutics in a report on Monday, March 2nd. UBS Group reaffirmed a “buy” rating on shares of Sionna Therapeutics in a report on Monday, March 2nd. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $53.00 target price on shares of Sionna Therapeutics in a report on Monday, January 5th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Sionna Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $50.57.

Sionna Therapeutics Trading Up 0.6%

The stock’s fifty day moving average price is $37.32 and its 200 day moving average price is $38.13. The stock has a market cap of $1.96 billion, a P/E ratio of -22.31 and a beta of 3.01.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.15.

Insider Transactions at Sionna Therapeutics

In other news, Director Peter A. Thompson sold 29,063 shares of the stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $44.58, for a total value of $1,295,628.54. Following the transaction, the director owned 3,530,702 shares of the company’s stock, valued at $157,398,695.16. This represents a 0.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Tpg Gp A, Llc sold 250,000 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $40.00, for a total transaction of $10,000,000.00. Following the completion of the transaction, the insider directly owned 6,494,962 shares in the company, valued at $259,798,480. The trade was a 3.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 311,906 shares of company stock valued at $12,759,732 in the last quarter. Insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On Sionna Therapeutics

A number of institutional investors have recently made changes to their positions in SION. Eventide Asset Management LLC purchased a new stake in shares of Sionna Therapeutics in the 4th quarter valued at $26,290,000. Vanguard Group Inc. boosted its stake in shares of Sionna Therapeutics by 81.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock valued at $33,620,000 after purchasing an additional 512,803 shares in the last quarter. State Street Corp boosted its stake in shares of Sionna Therapeutics by 188.7% in the 4th quarter. State Street Corp now owns 693,395 shares of the company’s stock valued at $28,526,000 after purchasing an additional 453,196 shares in the last quarter. Viking Global Investors LP boosted its stake in shares of Sionna Therapeutics by 8.2% in the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after purchasing an additional 242,427 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Sionna Therapeutics by 1,425.5% in the 3rd quarter. Millennium Management LLC now owns 214,085 shares of the company’s stock valued at $6,296,000 after purchasing an additional 200,051 shares in the last quarter.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.